Meitar Roz

Meitar Roz, an 8-year-old Israeli boy, became the focus of a significant national fundraising effort in 2026. Diagnosed with Duchenne Muscular Dystrophy (DMD)—a severe, progressive genetic disorder that leads to muscle degeneration and premature death—Meitar required a specialized gene therapy costing approximately $3.2 million. The case gained public attention after the Israeli state healthcare system denied a request to fund the treatment, placing the financial burden entirely on the family.

Meitar's parents, including his father who serves as an IDF reservist, launched an urgent public appeal to secure the necessary funds before a critical age-related medical window closed. The campaign resonated deeply within Israeli society, particularly against the backdrop of ongoing national security challenges and the high demand placed on reserve families. In a display of civil resilience and mutual responsibility (Arvut Hadadit), thousands of donors—ranging from close friends and family to total strangers—contributed to the cause.

The successful collection of $3.2 million highlights the strength of the Israeli social fabric and the community's willingness to bypass bureaucratic hurdles to save a child's life. While the medical outcome remains a private matter for the family, Meitar's story has sparked broader discussions regarding the state's responsibility toward citizens with rare diseases and the role of the public in filling gaps left by the national health basket. For The Zioneer, Meitar's case serves as a testament to the enduring spirit of the Israeli people and the specific challenges faced by those who serve the state while managing personal crises.